Status message

Active context: kki_bg_colors_yellow

A Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children with Neurodevelopmental Disabilities

Principal Investigator:
Robert
Findling

The purpose of this study is to establish the efficacy and safety of Circadin in children with neurodevelopmental disorders and to determine the dose, this randomized, placebo-controlled study is planned to evaluate the efficacy of a double-blind, 13 week treatment period with Circadin 2/5mg in improving maintenance of sleep, sleep latency and additional parameters in children with neurodevelopmental disabilities. The efficacy and safety of Circadin 2/5 mg will continue to be assessed during an open-label extension period of 13 weeks.

March is Brain Injury Awareness Month

Brain Injury Awareness Month

Help raise awareness and support for brain injury research, treatment and education. Learn more about our program.

Publications

Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.